Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model

Clinical and Experimental Immunology

Volumn 177, Issue 2, 2014, Pages 381-390

  Botte, D A C ^a   Noronha, I L ^a   Malheiros, D M A C ^a   Peixoto, T V ^a   De Mello, S B V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arthritis; Cytokines; Experimental lupus; Nephritis; MSH

Indexed keywords

AFAMELANOTIDE; ALPHA SMOOTH MUSCLE ACTIN; ANTINUCLEAR ANTIBODY; CD3 ANTIGEN; COMPLEMENT COMPONENT C3; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; MELANOCORTIN 1 RECEPTOR; PRISTANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LUPUS LIKE SYNDROME; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA;

ARTHRITIS; CYTOKINES; EXPERIMENTAL LUPUS; NEPHRITIS; Α-MSH;

ALPHA-MSH; ANIMALS; ANTIBODIES, ANTINUCLEAR; ARTHRITIS; CORTICOTROPIN-RELEASING HORMONE; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; KIDNEY GLOMERULUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTOR, MELANOCORTIN, TYPE 1; TERPENES;

EID: 84903974395     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12336     Document Type: Article

References (66)

1. Munoz LE, Janko C, Schulze C etal. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 2010; 10:38-42.
2. Davidson A, Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 2010; 6:13-20.
3. Zubair A, Frieri M. Lupus nephritis: review of the literature. Curr Allergy Asthma Rep 2013; 13:580-586.
4. Harle P, Straub RH, Wiest R etal. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis 2006; 65:51-56.
5. Shanks N, Moore PM, Perks P, Lightman SL. Alterations in hypothalamic-pituitary-adrenal function correlated with the onset of murine SLE in MRL+/+ and lpr/lpr mice. Brain Behav Immun 1999; 13:348-360.
6. Bomback AS, Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 2011; 12:91-96.
7. Patel HB, Leoni G, Melendez TM, Sampaio ALF, Perretti M. Melanocortin control of cell trafficking in vascular inflammation. Adv Exp Med Biol 2010; 681:88-106.
8. Giuliani D, Minutoli L, Ottani A etal. Melanocortins as potential therapeutic agents in severe hypoxic conditions. Front Neuroendocrinol 2012; 33:179-193.
9. Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann NY Acad Sci 2000; 917:239-247.
10. Taylor AW, Kitaichi N. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy. Brain Behav Immun 2008; 22:639-646.
11. Rheins LA, Cotleur AL, Kleier RS, Hoppenjans WB, Saunder DN, Nordlund JJ. Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J Invest Dermatol 1989; 93:511-517.
12. Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation 1994; 1:28-32.
13. Doi K, Hu X, Yuen PS etal. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008; 73:1266-1274.
14. Kolgazi M, Arbak S, Alican I. The effect of alpha-melanocyte stimulating hormone on gentamicin-induced acute nephrotoxicity in rats. J Appl Toxicol 2007; 27:183-188.
15. Lee SY, Jo SK, Cho WY, Kim HK, Won NH. The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine A nephrotoxicity. Transplantation 2004; 78:1756-1764.
16. Hart DA. Evidence that LiCl enhancement of the survival of NZB/W lupus mice is not mediated by alpha-melanocyte stimulating hormone. J Trace Microprobe Tech 1998; 16:111-118.
17. Miyaji T, Hu X, Star RA. Alpha-melanocyte-simulating hormone and interleukin-10 do not protect the kidney against mercuric chloride-induced injury. Am J Physiol Renal Physiol 2002; 282:F795-801.
18. Lindskog A, Ebefors K, Johansson ME etal. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010; 21:1290-1298.
19. Eves PC, Haycock JW. Melanocortin signalling mechanisms. Adv Exp Med Biol 2010; 681:19-28.
20. Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011:271694.
21. Bigazzi PE. Murine lupus induced by tetramethylpentadecane: an animal model of systemic human autoimmunity. Clin Immunol 2005; 114:97-99.
22. Smith-Bouvier DL, Divekar AA, Sasidhar M etal. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008; 205:1099-1108.
23. Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994; 180:2341-2346.
24. Sawyer TK, Sanfilippo PJ, Hruby VJ etal. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980; 77:5754-5758.
25. Dorr RT, Dawson BV, al-Obeidi F, Hadley ME, Levine N, Hruby VJ. Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH. Invest New Drugs 1988; 6:251-258.
26. Sinha PS, Schiöth HB, Tatro JB. Roles of the melanocortin-4 receptor in antipyretic and hyperthermic actions of centrally administered α-MSH. Brain Res 2004; 1001:150-158.
27. Ribeiro RA, Vale ML, Thomazzi SM etal. Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol 2000; 387:111-118.
28. Patten C, Bush K, Rioja I etal. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. Arthritis Rheum 2004; 50:3334-3345.
29. Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H, Reeves WH. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001; 60:2173-2180.
30. Dahlgren J, Takhar H, Anderson-Mahoney P, Kotlerman J, Tarr J, Warshaw R. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ Health 2007; 6:8.
31. Gomez-Sanmiguel AB, Martin AI, Nieto-Bona MP etal. Systemic alpha melanocyte stimulating hormone administration decreases arthritis-induced anorexia and muscle wasting. Am J Physiol Regul Integr Comp Physiol 2013; 304:R877-886.
32. Catania A, Gerloni V, Procaccia S etal. The anticytokine neuropeptide alpha-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules. Neuroimmunomodulation 1994; 1:321-328.
33. Raap U, Brzoska T, Sohl S etal. Alpha-melanocyte-stimulating hormone inhibits allergic airway inflammation. J Immunol 2003; 171:353-359.
34. Zhou LL, Wei W, Si JF, Yuan DP. Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediators Inflamm 2010; 2010:951210.
35. Ouyang S, Gong B, Li JZ etal. Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus. J Mol Med (Berl) 2012; 90:837-846.
36. Chun HY, Chung JW, Kim HA etal. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27:461-466.
37. Chae BS, Shin TY, Kim DK, Eun JS, Leem JY, Yang JH. Prostaglandin E-2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice. Arch Pharm Res 2008; 31:503-510.
38. Chowdhary VR, Grande JP, Luthra HS, David CS. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of pristane-induced lupus. Rheumatology (Oxf) 2007; 46:1405-1410.
39. Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J Leukoc Biol 2004; 76:227-236.
40. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998; 188:985-990.
41. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013; 72:118-128.
42. Airaghi L, Garofalo L, Cutuli MG etal. Plasma concentrations of alpha-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis. Nephrol Dial Transplant 2000; 15:1212-1216.
43. Urbonaviciute V, Starke C, Pirschel W etal. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus. Arthritis Rheum 2013; 65:1612-1623.
44. Llorente L, Richaud-Patin Y, Garcia-Padilla C etal. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43:1790-1800.
45. Figueiredo J, Ferreira AE, Silva RL etal. NDP-MSH inhibits neutrophil migration through nicotinic and adrenergic receptors in experimental peritonitis. Naunyn Schmiedebergs Arch Pharmacol 2013; 386:311-318.
46. Catania A, Lonati C, Sordi A, Leonardi P, Carlin A, Gatti S. The peptide NDP-MSH induces phenotype changes in the heart that resemble ischemic preconditioning. Peptides 2010; 31:116-122.
47. Haycock JW, Wagner M, Morandini R, Ghanem G, Rennie IG, Mac Neil S. Alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation in human melanocytes and melanoma cells. J Invest Dermatol 1999; 113:560-566.
48. Ichiyama T, Zhao H, Catania A, Furukawa S, Lipton JM. Alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation. Exp Neurol 1999; 157:359-365.
49. Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-tumor necrosis factor-alpha induced systemic lupus erythematosus. Open Rheumatol J 2012; 6:315-319.
50. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988; 331:356-358.
51. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143:3470-3475.
52. Makni K, Jarraya F, Khabir A etal. Renal alpha-smooth muscle actin: a new prognostic factor for lupus nephritis. Nephrology (Carlton) 2009; 14:499-505.
53. Hurtado A, Asato C, Escudero E etal. Clinicopathologic correlations in lupus nephritis in Lima, Peru. Nephron 1999; 83:323-330.
54. Lee TH, Jawan B, Chou WY etal. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med 2006; 8:764-772.
55. Xu PB, Mao YF, Meng HB, Tian YP, Deng XM. Sty39, a novel alpha-melanocyte-stimulating hormone analogue, attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice. Shock 2010; 35:308-314.
56. Yoshimoto S, Nakatani K, Iwano M etal. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis 2007; 50:47-58.
57. Tozawa F, Suda T, Dobashi I, Ohmori N, Kasagi Y, Demura H. Central administration of alpha-melanocyte-stimulating hormone inhibits corticotropin-releasing factor release in adrenalectomized rats. Neurosci Lett 1994; 174:117-119.
58. Wang JS, Tseng HH, Shih DF, Jou HS, Ger LP. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997; 77:404-411.
59. Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, Oates JC. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med 2008; 56:911-919.
60. Star RA, Rajora N, Huang J, Stock RC, Catania A, Lipton JM. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci USA 1995; 92:8016-8020.
61. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997; 99:1165-1172.
62. de Mello SB, Novaes GS, Laurindo IM, Muscara MN, Maciel FM, Cossermelli W. Nitric oxide synthase inhibitor influences prostaglandin and interleukin-1 production in experimental arthritic joints. Inflamm Res 1997; 46:72-77.
63. Siegrist W, Stutz S, Eberle AN. Homologous and heterologous regulation of alpha-melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines. Cancer Res 1994; 54:2604-2610.
64. Lee YS, Park JJ, Chung KY. Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury. Transplant Proc 2008; 40:2142-2144.
65. Gatti S, Colombo G, Turcatti F etal. Reduced expression of the melanocortin-1 receptor in human liver during brain death. Neuroimmunomodulation 2006; 13:51-55.
66. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol 2012; 50:1169-1173.